Andrew Davis

Mr. Davis has served as the Chief BD/M&A Officer at iNova Pharmaceuticals since September of 2017, leading all company transactions along with serving as a member of the company’s executive team. Prior to iNova Mr. Davis served as the Head of Oncology Business Development at Merck since December 2016. Prior to Merck, Mr. Davis served as the SVP of Business Development of Valeant Pharmaceuticals (now Bausch Health Companies) a global pharmaceutical, consumer products and medical device company, leading all transactions for the company from 2014 to December 2016. Prior this this role Mr. Davis had increasing roles of responsibility within the Business Development function at Valeant, joining the company in 2012. Prior to Valeant, he served as a management consultant at McKinsey & Co. focused on the healthcare space from 2007-2012. Mr. Davis received his B.A. in Economics from Boston University in Boston Massachusetts.